Ondine Biomedical (AIM:OBI) - Stock Price, News & Analysis

OBI Stock Overview

A life-sciences company, engages in the development and commercialization of antimicrobial therapies in Canada and internationally. More details

OBI fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Revenue is forecast to grow 66.03% per year

Earnings have grown 31.4% per year over the past 5 years

Risk Analysis

Volatile share price over the past 3 months compared to the UK market

Shareholders have been diluted in the past year

Does not have a meaningful market cap (£23M)

Currently unprofitable and not forecast to become profitable over the next 3 years

+ 1 more risk

Ondine Biomedical Inc. Competitors

Polarean Imaging

AIM:POLX

UK£18.4m

Belluscura

AIM:BELL

UK£16.8m

Inspiration Healthcare Group

AIM:IHC

UK£14.1m

ANGLE

AIM:AGL

UK£37.1m

Price History & Performance

Summary of all time highs, changes and price drops for Ondine Biomedical
Historical stock prices
Current Share Price	UK£0.081
52 Week High	UK£0.11
52 Week Low	UK£0.05
Beta	-0.080
11 Month Change	22.64%
3 Month Change	12.07%
1 Year Change	-4.41%
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	-85.99%

Recent updates

Is Ondine Biomedical (LON:OBI) In A Good Position To Invest In Growth?

Sep 28

Shareholder Returns

	OBI	GB Medical Equipment	GB Market
7D	0%	-2.1%	0.7%
1Y	-4.4%	-4.0%	6.1%

Return vs Industry: OBI matched the UK Medical Equipment industry which returned -4% over the past year.

Return vs Market: OBI underperformed the UK Market which returned 6.1% over the past year.

Price Volatility

Is OBI's price volatile compared to industry and market?
OBI volatility
OBI Average Weekly Movement	10.4%
Medical Equipment Industry Average Movement	6.1%
Market Average Movement	4.7%
10% most volatile stocks in GB Market	10.4%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: OBI's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: OBI's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of UK stocks.

About the Company

Founded	Employees	CEO	Website
1996	n/a	Carolyn Cross	ondinebio.com

Ondine Biomedical Inc., a life-sciences company, engages in the development and commercialization of antimicrobial therapies in Canada and internationally. Its product platform is Photodisinfection, a light-based antimicrobial technology that provides destruction of pathogens without causing antibiotic resistance. The company’s lead product is Steriwave, a nasal photodisinfection solutions that destroys bacteria, viruses, and fungi colonizing the nose which leads to healthcare-associated infections.

Ondine Biomedical Inc. Fundamentals Summary

How do Ondine Biomedical's earnings and revenue compare to its market cap?
OBI fundamental statistics
Market cap	UK£22.53m
Earnings (TTM)	-UK£8.09m
Revenue (TTM)	UK£925.87k

24.3x

P/S Ratio

-2.8x

P/E Ratio

Is OBI overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
OBI income statement (TTM)
Revenue	CA$1.63m
Cost of Revenue	CA$653.00k
Gross Profit	CA$981.00k
Other Expenses	CA$15.26m
Earnings	-CA$14.27m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.051
Gross Margin	60.04%
Net Profit Margin	-873.56%
Debt/Equity Ratio	0%

How did OBI perform over the long term?

See historical performance and comparison

OBI Stock Overview

Rewards

Risk Analysis

Ondine Biomedical Inc. Competitors

AIM:POLX

UK£18.4m

AIM:BELL

UK£16.8m

AIM:IHC

UK£14.1m

AIM:AGL

UK£37.1m

Price History & Performance

Recent News & Updates

Consensus EPS estimates fall by 48%

Price target increased by 9.1% to UK£0.60

Ondine Biomedical Inc. has completed a Follow-on Equity Offering in the amount of £9 million.

Ondine Biomedical Inc. has filed a Follow-on Equity Offering in the amount of £8.5 million.

Ondine Biomedical Inc. Receives Regulatory Approval to Market Steriwave Nasal Decolonization to Reduce Healthcare-Associated Infections in Patients Undergoing Surgery in the United Arab Emirates

Consensus estimates of losses per share improve by 44%

Recent updates

Consensus EPS estimates fall by 48%

Price target increased by 9.1% to UK£0.60

Ondine Biomedical Inc. has completed a Follow-on Equity Offering in the amount of £9 million.

Ondine Biomedical Inc. has filed a Follow-on Equity Offering in the amount of £8.5 million.

Ondine Biomedical Inc. Receives Regulatory Approval to Market Steriwave Nasal Decolonization to Reduce Healthcare-Associated Infections in Patients Undergoing Surgery in the United Arab Emirates

Consensus estimates of losses per share improve by 44%

First half 2024 earnings released: CA$0.032 loss per share (vs CA$0.041 loss in 1H 2023)

Ondine Biomedical Inc. announced that it expects to receive CAD 5 million in funding

Ondine Biomedical Inc. Announces Board and Committee Changes

Consensus EPS estimates fall by 38%

Full year 2023 earnings released: CA$0.073 loss per share (vs CA$0.10 loss in FY 2022)

Ondine Biomedical Inc. to Report Fiscal Year 2023 Final Results on Jun 07, 2024

Ondine Biomedical Inc. has completed a Follow-on Equity Offering in the amount of £3.037487 million.

New minor risk - Financial data availability

HCA Healthcare UK Approves the Steriwave Light-Activated Antimicrobial Developed by Ondine Biomedical Inc

New minor risk - Share price stability

Ondine Biomedical Inc. Announces Chief Financial Officer Changes

Ondine Biomedical Inc. Announces Steriwave Study Shows 77% Drop in Antibody Use

Ondine Biomedical Inc. Starts First UK Health Economics Study

New minor risk - Shareholder dilution

Ondine Biomedical Inc. Announces Appointment of Joseph P. Errico as Chief Financial Officer

Ondine Biomedical Inc. has completed a Follow-on Equity Offering in the amount of £2.75 million.

Ondine Biomedical Inc. has filed a Follow-on Equity Offering in the amount of £1 million.

First half 2023 earnings released: CA$0.041 loss per share (vs CA$0.044 loss in 1H 2022)

New minor risk - Financial data availability

New minor risk - Financial data availability

Ondine Biomedical Inc. to Report First Half, 2023 Results on Sep 25, 2023

New minor risk - Share price stability

Ondine Biomedical Inc. Announces Updated Phase 3 Clinical Trial

Ondine Biomedical Appoints Dr. Simon Sinclair as Chief Medical Officer

Full year 2022 earnings released: CA$0.10 loss per share (vs CA$0.63 loss in FY 2021)

Ondine Biomedical Inc. to Report Q1, 2023 Results on May 10, 2023

Ondine Biomedical Inc. Announces Publishing New Photodisinfection Study

Ondine Biomedical Inc. Announces Steriwave Receives Regulatory Approval in Mexico

Ondine Biomedical Inc. Receives Funding of Nearly $735,000 from Agriculture and Agri-Food Canada

Ondine Biomedical, Inc. Presents New Efficacy Data Against MRSA

Is Ondine Biomedical (LON:OBI) In A Good Position To Invest In Growth?

First half 2022 earnings released: CA$0.044 loss per share (vs CA$0.033 loss in 1H 2021)

Ondine Biomedical Inc. Provides Research Presented on Photodisinfection

Ondine Biomedical Reports Successful Topline Data from Phase 2 Nasal Photodisinfection Trial

Ondine Biomedical Inc. Completes Patient Recruitment for US Phase II Nasal Photodisinfection Trial

Ondine Biomedical Inc. Completes Randomised Controlled Study of Ondine

Ondine Biomedical Inc., Annual General Meeting, Jun 07, 2022

Insufficient new directors

Ondine Biomedical Inc. Announces That Photodisinfection Effective Against SARS-CoV-2

Ondine Biomedical Inc. Treats First Patients in Nasal Photodisinfection US Phase 2 for the Prevention of Post-Operative Infections

Ondine Biomedical Inc. Initiates A Clinical Trial of Its Steriwave™ Photodisinfection Technology for Nasal Disinfection in Covid-19 Patients

Ondine Biomedical Inc. has completed an IPO in the amount of £103.927594 million.

Insufficient new directors

Shareholder Returns

Price Volatility

About the Company

Ondine Biomedical Inc. Fundamentals Summary

24.3x

-2.8x

Earnings & Revenue